MAPT and dementia: Our results demonstrated that the dementia marker, (Aβ1-40 and Aβ1-42), levels reduced significantly on community-dwelling individuals of various ages after 4 weeks of treatment; (Aβ1-40 and Aβ1-42; 50–59 years; * p < 0.05, 60–69 years; * p < 0.05; 70–79 years; * p < 0.05) are shown in Figure S3; similarly, t-tau and p-tau levels reduced dramatically in different ages within 4 weeks of treatment; (60–69 years; ** p < 0.01; 70–79 years; * p < 0.05) are shown Figure S4.